Extension Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Subjects with Moderate to Severe Endometriosis-Associated Pain
Phase of Trial: Phase III
Latest Information Update: 20 Jul 2017
At a glance
- Drugs Elagolix (Primary)
- Indications Endometriosis; Pain
- Focus Pharmacodynamics; Registrational; Therapeutic Use
- Sponsors AbbVie
- 24 May 2017 Status changed from active, no longer recruiting to completed.
- 17 Jan 2017 Planned End Date changed from 1 Jun 2017 to 1 May 2017.
- 25 Jan 2016 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.